Cost-Effectiveness of Cervical Cancer Prevention in Central and Eastern Europe and Central Asia

Vaccine

Volumn 31, Issue S7, 2013, Pages

  Berkhof, Johannes ^a   Bogaards, Johannes A ^a   Demirel, Erhan ^a   Diaz, Mireia ^b   Sharma, Monisha ^c   Kim, Jane J ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Central Asia; Central Europe; Cost effectiveness; Eastern Europe; HPV; Mathematical model; Screening; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ALBANIA; ARMENIA; AZERBAIJAN; BELARUS; BOSNIA AND HERZEGOVINA; BULGARIA; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROATIA; CZECH REPUBLIC; DRUG COST; ESTONIA; FEMALE; GEORGIA (REPUBLIC); GROSS NATIONAL PRODUCT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUNGARY; KAZAKHSTAN; KYRGYZSTAN; LATVIA; LITHUANIA; MACEDONIA (REPUBLIC); MAJOR CLINICAL STUDY; MOLDOVA; MONTENEGRO (REPUBLIC); PAPANICOLAOU TEST; POLAND; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; ROMANIA; RUSSIAN FEDERATION; SCHOOL CHILD; SERBIA; SLOVAKIA; SLOVENIA; TAJIKISTAN; TURKMENISTAN; UKRAINE; UTERINE CERVIX CANCER; UZBEKISTAN;

CENTRAL ASIA; CENTRAL EUROPE; COST EFFECTIVENESS; EASTERN EUROPE; HPV; MATHEMATICAL MODEL; SCREENING; VACCINATION;

ADULT; ASIA, CENTRAL; CHILD; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; EUROPE, EASTERN; FEMALE; HUMANS; MODELS, THEORETICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84890239637     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.04.086     Document Type: Review

References (51)

1. Levi F., Lucchini F., Negri E., Franceschi S., la Vecchia C. Cervical cancer mortality in young women in Europe: patterns and trends. Eur J Cancer 2000, 36:2266-2271.
2. Arbyn M., Raifu A.O., Weiderpass E., Bray F., Anttila A. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer 2009, 45:2640-2648.
3. Franco E.L., Duarte-Franco E., Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ 2001, 164:1017-1025.
4. Poljak M., Maver P., Kocjan B., Cuschieri K.S., Rogovskaya S.I., Arbyn M., et al. Human Papillomavirus Prevalence and Type-Distribution, Cervical Cancer Screening Practices and Current Status of Vaccination Implementation in Central and Eastern Europe. Vaccine 2013, 31S:H59-H70.
5. Rogovskaya S.I., Shabalova I.P., Mikheeva I.V., Minkina G.N., Podzolkova N.M., Shipulina O.Y., et al. Human Papillomavirus Prevalence and Type-Distribution, Cervical Cancer Screening Practices and Current Status of Vaccination Implementation in Russian Federation, the Western Countries of the former Soviet Union, Caucasus Region and Central Asia. Vaccine 2013, 31S:H46-H58.
6. Prymula R., Anca I., Andre F., Bakir M., Czajka H., Lutsar I., et al. Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for the introduction of HPV vaccines. Eur J Pediatr 2009, 168:1031-1035.
7. Anttila A., von K.L., Aasmaa A., Fender M., Patnick J., Rebolj M., et al. Cervical cancer screening policies and coverage in Europe. Eur J Cancer 2009, 45:2649-2658.
8. Cuzick J., Clavel C., Petry K.U., Meijer C.J., Hoyer H., Ratnam S., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006, 119:1095-1101.
9. Ronco G., Giorgi-Rossi P., Carozzi F., Confortini M., Dalla P.P., Del M.A., et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010, 11:249-257.
10. Naucler P., Ryd W., Tornberg S., Strand A., Wadell G., Elfgren K., et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007, 357:1589-1597.
11. Rijkaart D.C., Berkhof J., Rozendaal L., van Kemenade F.J., Bulkmans N.W., Heideman D.A., et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012, 13:78-88.
12. Kitchener H.C., Almonte M., Thomson C., Wheeler P., Sargent A., Stoykova B., et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009, 10:672-682.
13. Ronco G., Giorgi-Rossi P., Carozzi F., Confortini M., Dalla P.P., Del M.A., et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008, 100:492-501.
14. Bogaards J.A., Coupe V.M., Xiridou M., Meijer C.J., Wallinga J., Berkhof J. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology 2011, 22:505-515.
15. World Development Indicators. Washington DC: The World Bank; 2013. Available at: (last accessed March 2013). http://data.worldbank.org/data-catalog/world-development-indicators.
16. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
17. Statistical Information System: CHOICE (CHOosing Interventions that are Cost Effective). Geneva: World Health Organization (WHO); 2013. Available at: (last accessed March 2013). http://www.who.int/choice/en/.
18. Countries eligible for support. Washington DC: GAVI Alliance; 2013. Available at: (last accessed March 2013). http://www.gavialliance.org/support/apply/countries-eligible-for-support/.
19. de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11:1048-1056.
20. Chesson H.W., Ekwueme D.U., Saraiya M., Markowitz L.E. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008, 14:244-251.
21. World Population Prospects: The 2010 Revision, CD-ROM Edition. New York: United Nations, Department of Economics and Social Affairs, Population Division; 2011.
22. WHO guide for standardization of economic evaluations of immunization programmes. Geneva: World Health Organization (WHO), Initiative for Vaccine Research; 2008.
23. Coupe V.M., Berkhof J., Bulkmans N.W., Snijders P.J., Meijer C.J. Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer 2008, 98:646-651.
24. Bulkmans N.W., Berkhof J., Bulk S., Bleeker M.C., van Kemenade F.J., Rozendaal L., et al. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 2007, 96:1419-1424.
25. Bulk S., Bulkmans N.W., Berkhof J., Rozendaal L., Boeke A.J., Verheijen R.H., et al. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Int J Cancer 2007, 121:361-367.
26. Berkhof J., Bulkmans N.W., Bleeker M.C., Bulk S., Snijders P.J., Voorhorst F.J., et al. Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol Biomarkers Prev 2006, 15:1268-1273.
27. Netherlands cancer incidence, mortality, and survival figures. Leiden: Netherlands Cancer Registry; 2013. Available at (last accessed at March 2013). http://www.cijfersoverkanker.nl/.
28. Brenner H., Francisci S., de Angelis R., Marcos-Gragera R., Verdecchia A., Gatta G., et al. Long-term survival expectations of cancer patients in Europe in 2000-2002. Eur J Cancer 2009, 45:1028-1041.
29. Ucakar V., Poljak M., Klavs I. Pre-vaccination prevalence and distribution of high-risk human papillomavirus (HPV) types in Slovenian women: A cervical cancer screening based study. Vaccine 2012, 30:116-120.
30. Bardin A., Vaccarella S., Clifford G.M., Lissowska J., Rekosz M., Bobkiewicz P., et al. Human papillomavirus infection in women with and without cervical cancer in Warsaw. Poland. Eur J Cancer 2008, 44:557-564.
31. Alibegashvili T., Clifford G.M., Vaccarella S., Baidoshvili A., Gogiashvili L., Tsagareli Z., et al. Human papillomavirus infection in women with and without cervical cancer in Tbilisi, Georgia. Cancer Epidemiol 2011, 35:465-470.
32. Quinn M., Babb P., Jones J., Allen E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 1999, 318:904-908.
33. Anttila A., Pukkala E., Soderman B., Kallio M., Nieminen P., Hakama M. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963-1995: recent increase in cervical cancer incidence. Int J Cancer 1999, 83:59-65.
34. Spaczynski M., Karowicz-Bilinska A., Kedzia W., Molinska-Glura M., Seroczynski P., Januszek-Michalecka L., et al. [Costs of population cervical cancer screening program in Poland between 2007-2009]. Ginekol Pol 2010, 81:750-756.
35. Obradovic M., Mrhar A., Kos M. Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia. Eur J Public Health 2010, 20:415-421.
36. GEO1R21A/support to breast and cervical cancer prevention - standard progress report. Tblisi, Republic of Georgia.: UNFPA, National Screening Center; 2010.
37. Goldie S.J., Gaffikin L., Goldhaber-Fiebert J.D., Gordillo-Tobar A., Levin C., Mahe C., et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 2005, 353:2158-2168.
38. Arbyn M., Autier P., Ferlay J. Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004. Ann Oncol 2007, 18:1423-1425.
39. Vanagas G., Padaiga Z., Kurtinaitis J., Logminiene Z. Cost-effectiveness of 12- and 15-year-old girls' human papillomavirus 16/18 population-based vaccination programmes in Lithuania. Scand J Public Health 2010, 38:639-647.
40. Suarez E., Smith J.S., Bosch F.X., Nieminen P., Chen C.J., Torvinen S., et al. Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine 2008, 26(Suppl 5):F29-F45.
41. Dasbach E.J., Nagy L., Brandtmuller A., Elbasha E.H. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary. J Med Econ 2010, 13:110-118.
42. Bray F., Lortet-Tieulent J., Znaor A., Brotons M., Poljak M., Arbyn M. Patterns and Trends in Human Papillomavirus-Related Diseases in Central and Eastern Europe and Central Asia. Vaccine 2013, 31S:H32-H45.
43. Guan P., Howell-Jones R., Li N., Bruni L., de Sanjosé S., Franceschi S., et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012, 131:2349-2359.
44. Wheeler C.M., Castellsague X., Garland S.M., Szarewski A., Paavonen J., Naud P., et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:100-110.
45. Bulkmans N.W., Berkhof J., Rozendaal L., van Kemenade F.J., Boeke A.J., Bulk S., et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007, 370:1764-1772.
46. Vink A., Bogaards J.A., van Kemenade F.J., de Melker H.E., Meijer C.J., Berkhof J. Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. Am J Epidemiol. 2013, 178(7):1161-1169.
47. Naucler P., Ryd W., Tornberg S., Strand A., Wadell G., Elfgren K., et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009, 101:88-99.
48. Rijkaart D.C., Berkhof J., van Kemenade F.J., Coupe V.M., Hesselink A.T., Rozendaal L., et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2012, 130:602-610.
49. Castle P.E., Stoler M.H., Wright T.C., Sharma A., Wright T.L., Behrens C.M. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 2011, 12:880-890.
50. Meijer C.J., Berkhof J., Castle P.E., Hesselink A.T., Franco E.L., Ronco G., et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009, 124:516-520.
51. Poljak M., Ostrbenk A., Seme K., Ucakar V., Hillemanns P., Bokal E.V., et al. Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening. J Clin Microbiol 2011, 49:1721-1729.